SAFETY ALERT: Bedford Laboratories Recalls Cytarabine for Injection, USP, 1g Per Vial

Share this article:

(ChemotherapyAdvisor) – Bedford Laboratories announced a nationwide voluntary recall February 16 for three lots of cytarabine for injection, USP 1g per vial (NDC #55390-133-01):

•        Lot 2066986 – Expiration date March 31, 2014

•        Lot 2111675 – Expiration date April 30, 2014

•        Lot 2131148 – Expiration date May 31, 2014

“This voluntary market recall is being conducted due to a post-release investigation of the manufacturing area which determined a potential elevated risk of a lack of sterility assurance for these specific lots. To date, there have been no reports of any adverse events for the lots being recalled,” the manufacturer noted.

These product lot numbers listed should not be used for patient care and should be quarantined immediately for return. Contact Bedford Laboratories Client Services Department at 800.562.4797 between 8 a.m. and 5 p.m., EST, Monday through Friday. Any adverse reactions experienced with any of the lots should be reported to 800.521.5169.

Adverse reactions or quality problems experienced with use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program: www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm.

Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

CTA Community Poll

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in General Oncology News

Low Life Expectancy Tied to Cancer Screening

Low Life Expectancy Tied to Cancer Screening

Second study shows no benefit from CRC screening more intensively than recommended.

Ruxolitinib May Help Those With Alopecia

Ruxolitinib May Help Those With Alopecia

New research suggests that a drug could restore hair growth in patients with one disease that can cause hair loss.

Retinoic Acid Inhibited by a Protein in Some

Retinoic Acid Inhibited by a Protein in Some

Retinoic acid is used to treat and help prevent the recurrence of a variety of cancers, but for some, the drug is not effective.